A clinical evaluation of Temafloxacin in paranasal sinusitis

• Published in: jibi to rinsho Vol. 40; no. 2; pp. 148 - 165
• Main Authors: OYAMA, Masaru, MIYAZAKI, Yasuhiro, UCHIZONO, Akihiro, SHIMA, Tetsuya, WATANABE, Soiku, MATSUNAGA, Shinya, SAMEJIMA, Atsushi, EGAWA, Masahiko, KAWAMURA, Shozo, ICHIKAWA, Ginichiro, ETO, Atsuko, ITABASHI, Takatsugu, WADA, Masashi, WATANABE, Hiroshi, NOMURA, Yasuya, KITAMURA, Ken, YAMASOBA, Tatsuya, KIKUCHI, Shigeru, MIZUNO, Masahiro, OKUNO, Taeko, ONISHI, Shinjiro, SO, Nagahiro, ITO, Yoriko, SAKAMOTO, Yutaka, KITA, Koichi, SASAKI, Toshikazu, MIYAKE, Hirosato, KIMURA, Hideshige, SHINKAWA, Atsushi, TAKAHASHI, Hideaki, BABA, Shunkichi, MIYAMOTO, Naoya, YAMAMOTO, Sinichiro, KOBAYASHI, Takehiro, ITO, Hiromi, YOKOTA, Akira, ITO, Haruo, ISAJI, Hiroko, SHIMADA, Junichiro, NAGATA, Soichiro, MATSUNAGA, Toru, HARADA, Tamotsu, ASAI, Hideyo, OZAKI, Masayoshi, ISHIDA, Minoru, HARADA, Yasuo, SUZUKI, Mamoru, HIRAKAWA, Katsuhiro, NAKATA, Masakaze, OMURA, Ryo, SATO, Shuji, SHIRANE, Makoto, SERA, Koji, SEKITANI, Toru, INOKUMA, Tetsuhiko, HIRATA, Tetsuyasu, NISHIKAWA, Masutoshi, NISHIKAWA, Keiko, OKUZONO, Tatsuya, OKUZONO, Yoshiko, TAHARA, Yasuhiko, KANEDA, Noritsugu, MOGI, Goro, UCHI, Hideyuki, AJISAKA, Koji, MORIYAMA, Ichiro, YANO, Hiromi, TSURUMARU, Hiroshi, IIDA, Humiko
• Format: Journal Article
• Language: Japanese
• Published: JIBI TO RINSHO KAI 20.03.1994
• Subjects: Temafloxacin; TMFX
• ISSN: 0447-7227; 2185-1034
• DOI: 10.11334/jibi1954.40.2_148

Temafloxacin (TMFX) evaluated for its efficacy safety, usefulness and also for its penetration into the pathological naso-sinus mucosa in paranasal sinusitis. The concentration of TMFX in the pathological naso-sinus tissues were as follows: MAXILLARY SINUS MUCOSA; 1.10-4.85μg/g (AVARAGE RATIO* 1.83) NASAL POLYP; 0.95-5.45μg/g (AVARAGE RATIO* 1.51) ETHMOID SINUS MUCOSA; 1.20-3.85μg/g (AVARAGE RATIO* 1.08) *(indicates the nasal tissue/serum) The efficacy rates judged by the doctor in charge were 88.0% in case of acute paranasal sinusitis, 81.5% in acute exacerbated paranasal sinusitis, 55.6% in chronic paranasal sinusitis and 80.3% in all cases. The efficacy rates judged by committee were 84.0% in the acute cases, 85.2% in the exacerbated cases, 44.4% in the chronic cases and 78.7% in all cases. The bacteriological eradication rates were 94.1% in gram-positive bacteria, 92.9% in gram-negative bacteria, 100% in anaerobic bacteria and 94.3% in all bacteria. The radiological efficacy rate was 63.3%. Side effects were observed in 3 cases and abnormal clinical laboratory findings occured in 2 cases, but these side effects were either mild or slight. The rate of usefulness was 77.4% in all cases. Based on these results, TMFX is there fore considerd to be useful in the treatment of paranasal sinusitis.